SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Supriya Lifescience - Quaterly Results

07 Feb 2024 Evaluate
The sales moved up 33.23% to Rs. 1400.74 millions for the December 2023 quarter as compared to Rs. 1051.40 millions during the year-ago period.The Net Profit of the company vaulted to 213.00% to Rs. 297.88  millions from Rs. 95.17 millions in the previous quarter.Operating Profit saw a handsome growth to 445.54 millions from 166.07 millions in the quarter ended December 2023.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202312 202212 % Var 202312 202212 % Var 202303 202203 % Var
Sales 1400.74 1051.40 33.23 4121.90 3186.67 29.35 4609.38 5300.49 -13.04
Other Income 30.65 25.64 19.54 84.50 75.26 12.28 94.89 75.77 25.23
PBIDT 445.54 166.07 168.28 1261.82 813.77 55.06 1383.87 2215.62 -37.54
Interest 4.94 10.14 -51.28 17.70 23.70 -25.32 30.84 41.98 -26.54
PBDT 440.60 155.93 182.56 1244.12 790.07 57.47 1353.03 2173.64 -37.75
Depreciation 39.60 29.50 34.24 118.96 88.08 35.06 118.15 101.18 16.77
PBT 401.00 126.43 217.17 1125.16 701.99 60.28 1234.88 2072.46 -40.41
TAX 103.12 31.26 229.88 303.32 185.70 63.34 336.30 554.35 -39.33
Deferred Tax 6.57 7.05 -6.81 21.76 10.96 98.54 29.49 32.46 -9.15
PAT 297.88 95.17 213.00 821.84 516.29 59.18 898.58 1518.11 -40.81
Equity 160.97 160.97 0.00 160.97 160.97 0.00 160.97 160.97 0.00
PBIDTM(%) 31.81 15.80 101.38 30.61 25.54 19.88 30.02 41.80 -28.18

Supriya Lifescience Share Price

636.90 -1.05 (-0.16%)
13-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1652.00
Dr. Reddys Lab 1235.20
Cipla 1211.30
Zydus Lifesciences 923.10
Lupin 2312.35
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×